Ticker > Company >

Aptus Pharma share price

Aptus Pharma Ltd.

BSE: 544529 SECTOR: Trading  403   0   0

132.39
+22.06 (19.99%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 132.39

Today's Low

₹ 112

52 Week High

₹ 111.9

52 Week Low

₹ 80.8

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

90.82 Cr.

Enterprise Value

95.96 Cr.

No. of Shares

0.69 Cr.

P/E

29.3

P/B

4.54

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  29.13

CASH

5.21 Cr.

DEBT

10.36 Cr.

Promoter Holding

72.89 %

EPS (TTM)

₹  4.52

Sales Growth

37.52%

ROE

70.99 %

ROCE

38.22%

Profit Growth

288.37 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year37.52%
3 YearNA
5 YearNA

Profit Growth

1 Year288.37%
3 YearNA
5 YearNA

ROE%

1 Year70.99%
3 Year49.81%

ROCE %

1 Year38.22%
3 Year26.16%

Debt/Equity

1.4867

Price to Cash Flow

-49.41

Interest Cover Ratio

9.9735

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2025 72.89 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 49.8057666666667% over the past 3 years.
  • Company has been maintaining healthy ROCE of 26.1597333333333% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 9.9735.
  • The company has an efficient Cash Conversion Cycle of 88.7279 days.
  • The company has a high promoter holding of 72.89%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 4.61544039556459.

 Limitations

  • The company has shown a poor profit growth of 0% for the Past 3 years.
  • The company has shown a poor revenue growth of 0% for the Past 3 years.
  • Company has negative cash flow from operations of -1.8382.
  • The company has a low EBITDA margin of 0% over the past 5 years.

Quarterly Result (All Figures in Cr.)

 Quarterly Data is not available for this company.Report us

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2023 Mar 2024 Mar 2025
Net Sales 13.9 17.86 24.56
Total Expenditure 13.28 16.31 19.71
Operating Profit 0.62 1.55 4.85
Other Income 0 0.03 0.08
Interest 0.14 0.24 0.47
Depreciation 0.18 0.21 0.27
Exceptional Items 0 0 0
Profit Before Tax 0.3 1.12 4.2
Tax 0.1 0.32 1.1
Net Profit 0.19 0.8 3.1
Adjusted EPS (Rs.) 1.3 5.32 1.24

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 0.3 0.3 5
Total Reserves 0.67 1.47 1.97
Borrowings 2.01 3.96 2.62
Other N/C liabilities 0.08 0.11 0.18
Current liabilities 3.13 4.14 12.08
Total Liabilities 6.18 9.97 21.85
Assets
Net Block 0.52 0.63 0.99
Capital WIP 0 0 0
Intangible WIP 0 0 0
Investments 0 0 0
Loans & Advances 0.01 0.01 0.05
Other N/C Assets 0 1.01 1.07
Current Assets 5.65 8.32 19.74
Total Assets 6.18 9.97 21.85
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2023 Mar 2024 Mar 2025
Profit from operations 0.3 1.12 4.2
Adjustment 0.32 0.43 0.65
Changes in Assets & Liabilities -0.68 -3.38 -5.57
Tax Paid -0.12 -0.34 -1.11
Operating Cash Flow -0.18 -2.17 -1.84
Investing Cash Flow -0.35 -0.3 -0.54
Financing Cash Flow 0.81 2.86 6.68
Net Cash Flow 0.28 0.38 4.3

Corporate Actions

Investors Details

PARTICULARS Sep 2025%
promoters 72.89
chatrabhuj vallabhbhai bu... 3.28
gaurang rameshchandra tha... 8.38
ghanshyam vinubhai pansur... 5.10
kapilbhai hasmukhbhai cha... 11.30
kripaliben mayank thakker... 8.38
kunjal piyushbhai unadkat... 8.38
milly chetan lalseta 8.38
riddhish natwarlal tanna 8.38
tejash maheshchandra hath... 11.30
 No Investors Data available for this company.Report us

Annual Reports

Title Link
Title Link
 No Annual reports exist for this company.Report us

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit and Research reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation and Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Aptus Pharma Stock Price Analysis and Quick Research Report. Is Aptus Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Aptus Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Aptus Pharma has a PE ratio of 27.310552407932 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Aptus Pharma has ROA of 19.4834% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Aptus Pharma has a Current ratio of 1.6333.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Aptus Pharma has a ROE of 70.9892%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Aptus Pharma has a Debt to Equity ratio of 1.4867 which means that the company has low proportion of debt in its capital.

  • Sales growth: Aptus Pharma has reported revenue growth of 37.5242% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Aptus Pharma for the current financial year is 19.7461488657325%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Aptus Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Aptus Pharma is Rs 4.5184. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Aptus Pharma in Ticker for free. Also, one can get the intrinsic value of Aptus Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Aptus Pharma FAQs

Q1. What is Aptus Pharma share price today?
Ans: The current share price of Aptus Pharma is Rs 123.4.

Q2. What is the market capitalisation of Aptus Pharma?
Ans: Aptus Pharma has a market capitalisation of Rs 84.6524 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Aptus Pharma?
Ans: The PE ratio of Aptus Pharma is 27.310552407932 and the P/B ratio of Aptus Pharma is 4.23555740141345, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Aptus Pharma share?
Ans: The 52-week high share price of Aptus Pharma is Rs 111.9, and the 52-week low share price of Aptus Pharma is Rs 80.8.

Q5. Does Aptus Pharma pay dividends?
Ans: Currently, Aptus Pharma does not pay dividends. Dividend yield of Aptus Pharma is around 0%.

Q6. What are the face value and book value of Aptus Pharma shares?
Ans: The face value of Aptus Pharma shares is Rs 10, while the book value per share of Aptus Pharma is around Rs 29.1343. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Aptus Pharma?
Ans: Aptus Pharma has a total debt of Rs 10.3568 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Aptus Pharma?
Ans: The ROE of Aptus Pharma is 70.9892% and ROCE of Aptus Pharma is 38.2221%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Aptus Pharma a good buy for the long term?
Ans: The Aptus Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Aptus Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Aptus Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Aptus Pharma’s financials?
Ans: You can review Aptus Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Aptus Pharma
X